An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance

Bioconjugate Chemistry

Volumn 16, Issue 2, 2005, Pages 346-353

  Hamann, Philip R ^a   Hinman, Lois M ^a   Beyer, Carl F ^a   Greenberger, Lee M ^a   Lin, Clara ^a   Lindh, Delores ^a   Menendez, Ana T ^a   Wallace, Rosalyn ^a   Durr, Frederick E ^a   Upeslacis, Janis ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; AMINO ACIDS; ANTIBIOTICS; CARBOHYDRATES; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; HYDROLYSIS; SULFUR COMPOUNDS; TARGETED DRUG DELIVERY; TUMORS;

ACTIVATED ESTER; ACTIVE DRUGS; ANTITUMOR ANTIBIOTICS; CALICHEAMICIN; CYTOTOXIC; DRUG RELEASE; DRUG-RESISTANCE; IN-VITRO; MULTIDRUG RESISTANCE; SOLID TUMORS;

ANTIBODIES;

AMIDE CONJUGATE; ANTINEOPLASTIC AGENT; CALICHEAMICIN; GLYCOCONJUGATE; MUCIN 1; MUCIN 1 ANTIBODY CALICHEAMICIN CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PH; SOLID TUMOR; TUMOR RESISTANCE;

EID: 20144375952     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc049795f     Document Type: Article

References (45)

1. I. J. Am. Chem. Soc. 109, 3464-3466.
2. I with glutathione in the presence of double-stranded DNA. J. Am. Chem. Soc. 116, 1255-1271.
3. 1. Enediyne Antibiotics as Antitumor Agents (Borders, D. B., and Doyle, T. W., Eds.) pp 137-160, Marcel Dekker, New York.
4. Lee, M. D., Ellestad, G. A., and Borders, D. B. (1991) Calicheamicins: Discovery, structure, chemistry, and interaction with DNA. Acc. Chem. Res. 24, 235-243.
5. Liu, C., and Chari, R. V. J. (1997) The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin. Invest. Drugs 6, 169-172.
6. Chari, R. V. J., Jackel, K. A., Bourret, L. A., Derr, S. M., Tadayoni, B. M., Mattocks, K. M., Shah, S. A., Liu, C., Blättler, W. A., and Goldmacher, V. S. (1995) Enhancement of the selectivity and antitumor activity of a CC-1065 analog through immunoconjugate formation. Cancer Res. 55, 4079-4084.
7. King, H. D., Staab, A. J., Pham-Kaplita, K., Yurgaitis, D., Firestone, R. A., Lasch, S. J., and Trail, P. A. (2003) BR96 conjugates of highly potent anthracyclines. Bioorg. Med. Chem. Lett. 13, 2119-2122.
8. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784 and 941a.
9. Baloglu, E., Miller, M. L., Roller, E. E., Leece, B. A., Goldmacher, V. S., and Chari, R. V. J. (2003) Studies toward novel taxoid-monoclonal antibody conjugates. Abstracts of Papers, 226th American Chemical Society National Meeting, New York, NY September 7-11, 2003, American Chemical Society: Washington, DC, 2003; MEDI-261.
10. Trail, P. A., Willner, D., Lasch, S. J. Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., and Hellström, K. E. (1993) Cure of xenografted human carcinomas by Br96-doxorubicin immunoconjugates. Science 261, 212-215.
11. Aboud-Pirak, E., Sergent, T., Otte-Slachmuylder, C., Abarca, J., Trouet, A., and Schneider, Y. J. (1988) Binding and endocytosis of a monoclonal antibody to a high molecular weight human fat globule membrane-associated antigen by cultured MCF-7 breast carcinoma cells. Cancer Res. 48, 3188-96.
12. DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M., Sridharan, L., Kunz, K., Hamann, P. R., Gorovits, B., Udata, C., Moran, J. K., Popplewell, A. G., Stephens, S., Frost, P., and Damle, N. K. (2004) Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 103, 1807-1814.
13. Y-positive human carcinoma cells and xenografts. Clin. Cancer Res. 10, 4538-4549.
14. Baker, T. S., Bose, C. C., Caskey-Finney, H. M., King, D. J., Lawson, A. D,. Lyons, A., Mountain, A., Owens, R. J., Rolfe, M. R., Sehdev, M., Yarranton, G. T., and Adair, J. R. (1994) Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Adv. Exp. Med. Biol. 1994, 35361-35382.
15. 111In-labeled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: Influence of prior administration of unlabeled hCTM01. Cancer Immunol. Immunother. 47, 39-46.
16. Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., and Upeslacis, J. (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res. 53, 3336-3342.
17. Hinman, L. M., Hamann, P. R., and Upeslacis, J. (1995) Preparation of conjugates to monoclonal antibodies. Enediyne Antibiotics as Antitumor Agents (Borders, D. B., and Doyle, T. W., Eds.) pp 87-105, Marcel Dekker, New York.
18. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., and Bernstein, I. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia, choice of linker. Bioconjugate Chem. 13, 40-46.
19. Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., and Gabizon, A. (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6, 1949-1957.
20. Gillespie, A. M., Broadhead, T. J., Chan, S. Y., Owen, J., Farnsworth, A., Sopwith, M., and Coleman, R. E. (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with epithelial ovarian cancer. Ann. Oncol. 11, 735-41.
21. Chan, S. Y., Gordon, A. Y., Coleman, R. Y., Hall, J. Y., Berger, M. S., Sherman, M. Y., Eten, C. Y., and Finkler, N. Y. (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. 52, 243-248.
22. Broadhead, T. J., Gillespie, A. M., Coleman, R. E., Owen, J., Skelton, L., Stephens, S., Farnsworth, A., Sopwith, M., and Chan, S. Y. (1998) Phase I study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with epithelial ovarian cancer: Immune response and pharmacokinetics following repeated intravenous administration. Proceedings of the American Society of Clinical Oncology, ASCO Annual Meeting, May 16-19, 1998, Los Angeles, CA, American Society of Clinical Oncology: Alexandria, VA, 1998, abstract 1693.
23. Bross, P. F., Beitz, J., Chen, G., Chen, X. H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A. R., Williams, G., and Pazdur, R. (2001) Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia, Clin. Cancer Res. 7, 1490-1496.
24. Davies, Q., Perkins, A. C., Fries, M., Watson, S., Lalani, E.-N., and Symonds, E. M. (1997) The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur. J. Nuclear Med. 24, 206-209.
25. Broadhead, T. J., Davies, Q., Van Hof, A. C., Molthoff, C. F. M., Perkins, A. C., Roos, J. C., Prinssen, W. M., Verheijen, R. H. M., den Hollander, W., Sopwith, M., Frier, M., Kenemans, P., and Symonds, E. M. (1998) Clinical study to investigate the potential of an engineered human monoclonal antibody, hCTM01, for targeted chemotherapy of ovarian cancer. Tumor Target. 3, 55-57.
26. Walter, R. B., Raden, B. W., Cronk, M. R., Bernstein, I. D., Appelbaum, F. R., and Banker, D. E. (2004) The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 103, 4276-4284.
27. Melchers, F. (1970) Biosynthesis of the carbohydrate portion of immunoglobulins. Biochem. J. 119, 765-772.
28. Epstein, A., Marder, R. J., Winter, J., Stathopoulos, E., Chen, F.-M., Parker, J. W., and Taylor, C. R. (1987) Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 47, 830-840.
29. Newman, E. M., Lu, Y., Kashani-Sabet, M., Kesavan, V., and Scanlon, K. J. (1988) Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. Biochem. Pharmacol. 37, 443-447.
30. Wallace, R. E., Lindh, D., and Durr, F. E. (1989) Arabinofuranosyl-5- azacytosine: Activity against human tumors in athymic mice. Cancer Chemother. Pharm. 25, 117-123.
31. Zhang, X. P., Ritke, M. K., Yalowich, J. C., Slovak, M. L., Ho, J. P., Collins, K. I., Annable, T., Arceci, R. J., Durr, F. E., and Greenberger, L. M. (1994) P-glycoprotein mediates profound resistance to bisantrene. Oncol. Res. 6, 291-301.
32. Van Dyke, R. W., Root, K. V., Schreiber, J. H., and Wilson, J. M. (1992) Role of CFTR in lysosomal acidification. Biochem. Biophys. Res. Commun. 184, 300-305.
33. Ohkuma, S., and Poole, B. (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. U.S.A. 75, 3327-3331.
34. Shen, D.-W., Fojo, A., Chin, J. E., Roninson, I. B., Richet, N., Pastan, I., and Gottesman, M. M. (1986) Human multidrug-resistant cell lines: Increased MDR1 expression can precede gene amplification. Science 232, 643-645.
35. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D. A., and Bernstein, I. (2002) A potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 13, 47-58.
36. Mamsoor, M. A., Svardal, A. M., and Ueland, P. M. (1992) Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal. Biochem. 200, 218-229.
37. Mistry, P., and Harrap, K. R. (1991) Historical aspects of glutathione and cancer chemotherapy. Pharm. Ther. 49, 125-132.
38. Shen, D.-W., Cardarelli, C., Hwang, J., Cornwell, M., Richet, N., Ishii, S., Pastan, I., and Gottesman, M. M. (1986) Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 261, 7762-7770.
39. El-Akawi, Z. Zdanowicz, J., Creaven, P. J., Abu-Hadid, M., Perez, R., and Pendyala, L. (1996) Induction of γ-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. Oncol. Res. 8, 415-423.
40. Goto, S., Yoshida, K., Morikawa, T. Urata, Y., Suzuki, K., and Kondo, T. (1995) Augmentation of transport for cis-platin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res. 55, 4297-4301.
41. Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tambe, M., Wang, H., Sodha, S., Hamada, H., Yoshikawa, H., Kondo, T., and Bannai, S. (2003) Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 88, 951-956.
42. Berger, M. S., Leopold, L. H., Dowell, J. A., Korth-Bradley, J. M., and Sherman, M. L.. (2002) Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest. New Drugs 20, 395-406.
43. Linenberger, M. L., Hong, T., Flowers, D., Sievers, E. L., Gooley, T. A., Bennett, J. M., Berger, M. S., Leopold, L. H., Appelbaum, F. R., and Bernstein, I. D. (2001) Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98, 988-994.
44. Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., and Gabizon, A. (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6, 1949-1957.
45. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Shochat, D., and Mountain, A. (2002) A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjugate Chem. 16, 354-360.